In a filing with the U.S. Securities and Exchange Commission, AstraZeneca said it withdrew its notification of the pending merger with the Federal Trade Commission. That restarts a 30-day clock and ...

An experimental drug from AstraZeneca succeeded in a late-stage trial in an autoimmune condition called generalized myasthenia gravis, positioning the company to grow a business it inherited when ...

New long-term data will further substantiate potential of gefurulimab as once-weekly subcutaneous self-administered treatment for adults with gMG Additional data will showcase commitment to advancing ...

Alexion, AstraZeneca Rare Disease, will deliver 16 presentations, including three oral presentations, across hypophosphatasia (HPP), chronic hypoparathyroidism (HypoPT) and early research at the ...

“We had three very unique patients—three different walks of life, three different communities, from various states—yet their journey led them all to a very common place,” Tamar Thompson, Alexion's ...

AstraZeneca ( AZN ), a biopharmaceutical company, said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Enhertu for an additional early ...

The book focuses on providing kids and their caregivers with information in four key areas: how aHUS affects the kidneys, its impact on daily life, details of the patient journey, and tips for dealing ...

WILMINGTON, Del.--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine ...

Despite the primary endpoint miss, AstraZeneca hopes to bring efzimfotase alfa to patients with hypophosphatasia.

LogicBio acquisition to build on current collaborations and advancements in genomic medicine LEXINGTON, Mass., Oct. 3, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (TXMD) (NASDAQ: LOGC), a ...